Oryzon Genomics S.A. (LON:0RDB)

Market Cap	210.54M +174.2%
Revenue (ttm)	6.42M -45.5%
Net Income	-2.41M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	114.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	357
Average Volume	2,144
Open	3.130
Previous Close	3.130
Day's Range	3.110 - 3.130
52-Week Range	1.570 - 4.000
Beta	0.37
RSI	42.00
Earnings Date	Feb 27, 2026

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RDB

Financial Performance

In 2024, Oryzon Genomics's revenue was $7.62 million, a decrease of -51.43% compared to the previous year's $15.69 million. Losses were -$3.79 million, 2.39% more than in 2023.

Financial numbers in USD